While many Americans rely on generic drugs as an inexpensive way to treat common ailments, common essential medications can vary in quality from manufacturer to manufacturer and even batch to batch of, especially when a drug goes generic. The team at New Haven-based Valisure saw a market opportunity and developed techniques and technology to make sure that each batch of medicine they distribute has been tested for many of the most important properties, like dosage, dissolution and contaminants.
Our speaker at WHIPgroup’s Meetup on Tuesday, June 16, is David Light, CEO of Valisure. A repeat entrepreneur who’s worked for several successful biotech startups. David is a repeat entrepreneur who’s worked for several successful biotech startups. He will share his insights into the current world of healthcare and the opportunities presenting themselves to biotech leaders with the background and drive to get things done.
By Wesley W. Whitmyer, Jr. Not every person is a match for every job. Patents are expensive and complicated legal documents. No less authority than the US Supreme Court noted long ago that “[t]he specification [Read More…]
By William L Birks III In a patent infringement suit, plaintiffs often seek damages for lost sales of infringing products. While this is the most obvious source of recovery, opportunities for larger damage rewards may [Read More…]
WHIPgroup recently made appearances on behalf of client WhitServe LLC in two IPRs brought by Dropbox Inc. The IPRs were filed in response to WhitServe’s patent infringement lawsuit against Dropbox Inc. in the District of Delaware. WhitServe’s U.S. Patent [Read More…]